EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses

Sharon Jan, Christopher A Sumner, Grecia A Sandoval, Stephen Won, Laura D Weinstock, Anna L Lara, Anupama Sinha, Megan Shelby, Emilia Grzesiak, Andre Goncalves, Mary Silva, Emily Engelhart und 11 weitere

Antibody Therapeutics · 03.09.2026

DOI: 10.1093/abt/tbag046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 03.09.2026. Verfasst von Sharon Jan und 22 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Energy’s National Nuclear Security Administration.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Junín virus (JUNV) is the causative agent of Argentine Hemorrhagic Fever (AHF) with the capacity for human-to-human transmission. AHF is endemic to Argentina and is prevented in at-risk populations with the regionally approved Candid#1 live attenuated vaccine (JUNV/C#1). However, there are barriers to US FDA (Federal Drug Administration) or EMA (European Medicines Agency) licensure of JUNV/C#1, and there are no approved post-exposure medical countermeasures (MCMs). The CR1-series of monoclonal antibodies (mAbs), isolated from JUNV/C#1 recipients by the Abraham lab (Clark et. al, 2018) have been proposed as MCMs for the treatment of AHF.

Methods

Several of these antibodies were evaluated here for potential cross-protection to other pathogenic New World Arenaviruses (NWAV) by binding, mutational scanning, and chimeric virus neutralization assay. Protective efficacy against challenge with authentic JUNV was determined by prophylactic administration in a guinea pig model of AHF.

Results

Although mAb cross-binding to the soluble receptor binding domain of the viral glycoprotein (sGP1) from multiple strains of JUNV, and the related hemorrhagic fever causing NWAV, Machupo was observed, these mAbs did not cross bind other NWAVs: Guanarito, Sabia, and Chapare. The Hartley outbred guinea pig model of AHF was used to demonstrate the protective efficacy of CR1-28 for the prevention of AHF-like disease.

Conclusions

This study provides the first proof-of-concept evidence for mAb prophylaxis of AHF. However, the results also demonstrated that CR1-10 is not protective as a monotherapy.

Förderung

  • U.S. Department of Energy’s National Nuclear Security Administration

Zitieren

APA

Jan, S., Sumner, C. A., Sandoval, G. A., Won, S., Weinstock, L. D., Lara, A. L., Sinha, A., Shelby, M., Grzesiak, E., Goncalves, A., Silva, M., Engelhart, E., Rangarajan, S., Kerzic, M. C., Mitchell, C. A., Allmon, E. B., Goez-Gazi, Y., Dutton, J. W., Carrion, R., …, & Johnson, D. M. (2026). Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag046

Vancouver

Jan S, Sumner CA, Sandoval GA, Won S, Weinstock LD, Lara AL, et al. Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses. Antibody Therapeutics. 2026. doi:10.1093/abt/tbag046

BibTeX
@article{Jan2026,
  author = {Jan, Sharon and Sumner, Christopher A and Sandoval, Grecia A and Won, Stephen and Weinstock, Laura D and Lara, Anna L and Sinha, Anupama and Shelby, Megan and Grzesiak, Emilia and Goncalves, Andre and Silva, Mary and Engelhart, Emily and Rangarajan, Sneha and Kerzic, Melissa C and Mitchell, Carter A and Allmon, Elizabeth B and Goez-Gazi, Yenny and Dutton, John W and Carrion, Ricardo and Desautels, Thomas and Alfson, Kendra J and Cirimotich, Chris M and Johnson, Dylan M},
  title = {Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses},
  journal = {Antibody Therapeutics},
  year = {2026},
  doi = {10.1093/abt/tbag046}
}
Kostenlos starten →